Digestive & weight Small-molecule NNMT inhibitor
5-Amino-1MQ
Regulatory status
Status at a glance
503A compounding status
Not nominated
We found no pending nomination for the 503A bulks list. Unless the substance has another legal pathway (for example, a USP monograph or use in an FDA-approved drug), 503A pharmacies generally may not compound with it.
- FDA approval
- Not FDA-approved for any use
- 503B outsourcing
- Not determined
- Anti-doping (WADA)
- Not on the WADA Prohibited List
- DEA schedule
- Not a controlled substance
About peptide status
Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.
This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.
If you think you are having a medical emergency, call 911.
Key takeaway
5-Amino-1MQ is a small-molecule NNMT inhibitor that, in cell studies, increases NAD+ and SAM and suppresses fat production in fat cells. In diet-induced obese mice, a potent NNMT inhibitor reduced body weight and fat mass without changing food intake. As of 2026, no human trials have been published, and it is not a peptide. It is not approved by the FDA.
At a glance
- What it is
- Blocks an enzyme called NNMT; despite being sold alongside peptides, not technically a peptide
- FDA status
- Marketed in the wellness and longevity space for metabolism and fat loss, but not FDA-approved for any use
- Research
- Almost all in animals, with no completed human trials
- Evidence strength
- Low research
Summary
5-Amino-1MQ is an NNMT-inhibiting small molecule, not a peptide. See what animal studies show, why human data is missing, and its non-FDA-approved status.
What is 5-Amino-1MQ?
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small synthetic molecule that inhibits an enzyme called nicotinamide N-methyltransferase, or NNMT. It is not a peptide. Peptides are short chains of amino acids, whereas 5-Amino-1MQ is a small-molecule methylquinolinium compound. It is often grouped with research peptides, but it belongs to a different chemical class.
How does 5-Amino-1MQ work?
NNMT is an enzyme that becomes more active in fat tissue in obesity. In cell studies, inhibiting it increases NAD+ and SAM and suppresses fat production in fat cells. In diet-induced obese mice, a potent NNMT inhibitor reduced body weight and fat mass without changing how much the animals ate. These findings come from animal and cell studies, not from humans.
Is it FDA-approved?
Safety note
Status: Marketed in the wellness and longevity space for metabolism and fat loss, but not FDA-approved for any use
Category: Wellness and performance · Primary body area: Digestive & weight
No. 5-Amino-1MQ has never been approved by the FDA for any use and, unlike an approved drug, it has not gone through completed human trials.
What does the research show?
Editor’s note
Evidence strength: Low research (0 human · 2 animal/cell studies)
Its evidence is limited to animal and cell studies of NNMT inhibition and fat loss, with no completed human trials.
The research is almost entirely preclinical. The main evidence comes from animal and cell work, including these two studies:
| Study | Model | Finding |
|---|---|---|
| Foundational NNMT-inhibitor study | Mice | First showed NNMT inhibitors reduce obesity |
| 2022 study | Obese mice | NNMT inhibition combined with a low-fat diet reduced body weight and adiposity |
There are no completed randomized controlled human trials, so its effects and safety in people remain unknown.
Sources: preclinical studies cited above are indexed on PubMed and cited by DOI where used, including the 2017 NNMT-inhibitor study in Biochemical Pharmacology (DOI: 10.1016/j.bcp.2017.11.007) and a 2022 study in Scientific Reports (DOI: 10.1038/s41598-021-03670-5). This document is educational research and does not constitute medical advice, a health claim, or an offer to sell; 5-Amino-1MQ is not approved by the FDA, and its safety and effectiveness in humans have not been established.
Registered human trials
0 registered human trials on ClinicalTrials.gov that we reviewed
Sources
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
Compare every peptide’s status in the peptide regulatory status database
More for Digestive & weight
View all digestive & weight peptides →- In clinical trials Digestive & weight
Amycretin
Amycretin is an investigational single-molecule drug that activates both the GLP-1 receptor and the amylin receptor, being developed by Novo Nordisk in subcutaneous and oral forms for weight management. In a 2025 phase 1b/2a trial of 125 adults with overweight or obesity, the 60 mg group lost 24.3% of body weight at 36 weeks versus 1.1% on placebo (p < 0.0001), though many participants withdrew. As of 2026 it is not approved anywhere and is moving into Phase 3 testing.
- Not FDA-approved Digestive & weight
Aod-9604
AOD-9604 is a modified fragment of the tail end of human growth hormone, developed as a fat-loss drug. Its human obesity trials failed to beat placebo, and development for obesity was halted. As of 2026 it is not FDA-approved and is banned in sport.
- In clinical trials Digestive & weight
Apraglutide
Apraglutide is an investigational long-acting GLP-2 analog, developed by Ironwood Pharmaceuticals as a once-weekly injection for short bowel syndrome, a condition in which people depend on intravenous nutrition because their intestine cannot absorb enough. In a Phase 3 trial it reduced the need for that intravenous support compared with placebo. As of 2026 it is not approved, and the FDA has asked for an additional confirmatory trial.
- Not FDA-approved Digestive & weight
Bpc-157
BPC-157 is a synthetic 15-amino-acid peptide studied for tissue and gut repair, and 35 of the 36 studies in a 2025 systematic review were animal or lab work. The one human report, a retrospective series of 12 patients with chronic knee pain, found that seven (58%) described relief lasting more than 6 months. It had no control group, effect size, or safety data. BPC-157 is not FDA-approved, is prohibited in sport, and remains unsettled in FDA compounding review.
- In clinical trials Digestive & weight
Brilacidin
Brilacidin is an investigational defensin-mimetic, a small molecule designed to imitate the body's own host-defense peptides, developed by Innovation Pharmaceuticals for oral mucositis and studied as an antibacterial and antiviral agent. Its human results to date have been reported mainly through company announcements rather than peer-reviewed trials, while published support is largely laboratory-based. As of 2026 it is not approved for any use.
- In clinical trials Digestive & weight
Cagrilintide
Cagrilintide is an investigational long-acting amylin analog, developed by Novo Nordisk as a once-weekly injection for weight management. In a Phase 2 trial, it produced weight loss over 26 weeks, but most of its late-stage development is as the amylin component of the combination drug CagriSema, though a standalone Phase 3 trial has started. As of 2026, cagrilintide is not approved on its own.